Acquired resistance to mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models

Resistance to targeted EGFR inhibitors is likely to develop in EGFR mutant lung cancers. Early identification of innate or acquired resistance mechanisms to these agents is essential to direct development of future therapies. We describe the detection of heterogeneous mechanisms of resistance within...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Res
Autori principali: Eberlein, Catherine A., Stetson, Daniel, Markovets, Aleksandra A., Al-Kadhimi, Katherine J., Lai, Zhongwu, Fisher, Paul R., Meador, Catherine B., Spitzler, Paula, Ichihara, Eiki, Ross, Sarah J., Ahdesmaki, Miika J., Ahmed, Ambar, Ratcliffe, Laura E., Christey O’Brien, Elizabeth L., Barnes, Claire H., Brown, Henry, Smith, Paul D., Dry, Jonathan R., Beran, Garry, Thress, Kenneth S., Dougherty, Brian, Pao, William, Cross, Darren A. E.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4605607/
https://ncbi.nlm.nih.gov/pubmed/25870145
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-3167
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi